Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher E M Griffiths

Showing results (231-240 of 337) with videos related to

Pageof 34
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|June 26, 2015
Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritisMeghna Jani, Hector Chinoy, Richard B Warren, et al.
The British Journal of Dermatology|May 31, 2024
The impact of irritant challenge on the skin barrier and myeloid-resident immune cells in women who are postmenopausal is modulated by hormone replacement therapyOrsolya Kiss, Rajia Bahri, Rachel E B Watson, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2021
Serious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2Peter Foley, Kristian Reich, Andrew Blauvelt, et al.
The Journal of Investigative Dermatology|October 22, 2017
Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)Zenas Z N Yiu, Catherine H Smith, Darren M Ashcroft, et al.
Trials|August 31, 2018
A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trialVictoria Cornelius, Rosemary Wilson, Suzie Cro, et al.
The Journal of Investigative Dermatology|October 30, 2017
Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)Ireny Y K Iskandar, Richard B Warren, Mark Lunt, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|August 20, 2015
P16INK4a Positive Cells in Human Skin Are Indicative of Local Elastic Fiber Morphology, Facial Wrinkling, and Perceived AgeMariëtte E C Waaijer, David A Gunn, Peter D Adams, et al.
The British Journal of Dermatology|November 12, 2023
Characteristics of 'super responders' and 'super nonresponders' to first biologic monotherapy for psoriasis: a nested case-control studyKayleigh J Mason, Oras A Alabas, Nick Dand, et al.
Journal of Anatomy|May 27, 2020
Heterogeneity of fibrillin-rich microfibrils extracted from human skin of diverse ethnicityAbigail K Langton, Mark Hann, Patrick Costello, et al.
Dermatology and Therapy|November 23, 2021
Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE StudyToni Maria Klein, Christine Blome, C Elise Kleyn, et al.
Pageof 34

Showing results (231-240 of 337) with videos related to

Sort By:
Pageof 34
Arthritis & Rheumatology (Hoboken, N.J.)|June 26, 2015
Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritisMeghna Jani, Hector Chinoy, Richard B Warren, et al.
The British Journal of Dermatology|May 31, 2024
The impact of irritant challenge on the skin barrier and myeloid-resident immune cells in women who are postmenopausal is modulated by hormone replacement therapyOrsolya Kiss, Rajia Bahri, Rachel E B Watson, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2021
Serious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2Peter Foley, Kristian Reich, Andrew Blauvelt, et al.
The Journal of Investigative Dermatology|October 22, 2017
Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)Zenas Z N Yiu, Catherine H Smith, Darren M Ashcroft, et al.
Trials|August 31, 2018
A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trialVictoria Cornelius, Rosemary Wilson, Suzie Cro, et al.
The Journal of Investigative Dermatology|October 30, 2017
Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)Ireny Y K Iskandar, Richard B Warren, Mark Lunt, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|August 20, 2015
P16INK4a Positive Cells in Human Skin Are Indicative of Local Elastic Fiber Morphology, Facial Wrinkling, and Perceived AgeMariëtte E C Waaijer, David A Gunn, Peter D Adams, et al.
The British Journal of Dermatology|November 12, 2023
Characteristics of 'super responders' and 'super nonresponders' to first biologic monotherapy for psoriasis: a nested case-control studyKayleigh J Mason, Oras A Alabas, Nick Dand, et al.
Journal of Anatomy|May 27, 2020
Heterogeneity of fibrillin-rich microfibrils extracted from human skin of diverse ethnicityAbigail K Langton, Mark Hann, Patrick Costello, et al.
Dermatology and Therapy|November 23, 2021
Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE StudyToni Maria Klein, Christine Blome, C Elise Kleyn, et al.
Pageof 34